首页> 美国卫生研究院文献>BMC Cancer >Lack of relationship between TIMP-1 tumour cell immunoreactivity treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
【2h】

Lack of relationship between TIMP-1 tumour cell immunoreactivity treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer

机译:晚期上皮性卵巢癌患者TIMP-1肿瘤细胞免疫反应性治疗效果与预后之间缺乏相关性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTissue inhibitor of metalloproteinase 1 (TIMP-1) is a natural inhibitor of the matrix metalloproteinases (MMPs) which are proteolytic enzymes involved in degradation of extracellular matrix thereby favoring tumour cell invasion and metastasis. TIMP-1 activity in tumour tissue may therefore play an essential role in the progression of a malignant tumour.The primary aim of the present study was to evaluate TIMP-1 protein immunoreactivity in tissue from primary ovarian cancer patients and associate these findings with the course of the disease including response to treatment in the individual patient.
机译:背景金属蛋白酶1(TIMP-1)的组织抑制剂是基质金属蛋白酶(MMP)的天然抑制剂,基质金属蛋白酶是参与细胞外基质降解从而促进肿瘤细胞侵袭和转移的蛋白水解酶。因此,肿瘤组织中TIMP-1的活性可能在恶性肿瘤的发展中起着至关重要的作用。本研究的主要目的是评估原发性卵巢癌患者组织中TIMP-1蛋白的免疫反应性,并将这些发现与治疗过程联系起来。疾病,包括对单个患者的治疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号